While the dates are only guidelines / estimates as the trial can be stopped early for overwhelming efficacy it clearly demonstrates that the company needs to finalise a lucrative partnership deal as we simply don’t have the cash runway to accomodate these timelines no matter what cost cutting has been done or what is being said in CCs or on HC
https://www.clinicaltrials.gov/study/NCT06325566?intr=Rexlemestrocel-L&rank=3
2024 Here we go again., page-241
-
- There are more pages in this discussion • 638 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |